Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of "Buy" by Analysts

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have been given a consensus rating of "Buy" by the eight brokerages that are covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $53.00.

Several equities research analysts recently weighed in on the stock. William Blair assumed coverage on shares of Dianthus Therapeutics in a research report on Wednesday, July 2nd. They issued an "outperform" rating on the stock. Robert W. Baird reduced their price target on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 13th. Finally, HC Wainwright restated a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th.

Institutional Trading of Dianthus Therapeutics

A number of large investors have recently made changes to their positions in DNTH. TCG Crossover Management LLC purchased a new stake in shares of Dianthus Therapeutics during the fourth quarter valued at $32,735,000. RA Capital Management L.P. lifted its stake in Dianthus Therapeutics by 53.6% in the first quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company's stock worth $52,003,000 after acquiring an additional 1,000,333 shares during the period. Braidwell LP lifted its stake in Dianthus Therapeutics by 144.4% in the fourth quarter. Braidwell LP now owns 1,206,589 shares of the company's stock worth $26,304,000 after acquiring an additional 712,902 shares during the period. Vestal Point Capital LP lifted its stake in Dianthus Therapeutics by 172.2% in the fourth quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company's stock worth $23,435,000 after acquiring an additional 680,000 shares during the period. Finally, Octagon Capital Advisors LP lifted its stake in Dianthus Therapeutics by 20.8% in the fourth quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company's stock worth $46,002,000 after acquiring an additional 363,500 shares during the period. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock traded up $0.71 on Tuesday, hitting $19.75. 88,723 shares of the company traded hands, compared to its average volume of 314,755. The stock has a market capitalization of $635.29 million, a P/E ratio of -6.86 and a beta of 1.38. Dianthus Therapeutics has a 52 week low of $13.36 and a 52 week high of $32.27. The business has a 50-day simple moving average of $18.60 and a 200 day simple moving average of $20.27.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.04. The firm had revenue of $1.16 million for the quarter, compared to analysts' expectations of $0.81 million. Dianthus Therapeutics had a negative net margin of 1,544.23% and a negative return on equity of 29.26%. Research analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.